Seattle Genetics Inc., of Bothell, Wash., reported second quarter revenues of $108.2 million, including $74.3 million in net sales of Adcetris (brentuximab vedotin) in the U.S. and Canada, compared to revenues of $95.4 million in the second quarter of 2016.